Individuals who resisted COVID-19 had similar IgG titers and did not exhibit enhanced expression of non-IgG1 subclasses, pointing to the potential for Fc-glycosylation differences controlling FcγR3B binding. The gene discussed is FCGR3B; the disease is COVID-19.